<DOC>
	<DOCNO>NCT02131493</DOCNO>
	<brief_summary>This study randomize , open-label , control study compare efficacy S-1 combination gemcitabine gemcitabine alone adjuvant treatment patient surgically resect pancreatic adenocarcinoma .</brief_summary>
	<brief_title>S-1 Gemcitabine v Gemcitabine Alone Adjuvant Chemotherapy Patients With Resected Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Histologically confirm resected ductal pancreatic adenocarcinoma macroscopic complete resection ( R0 R1 ) . Subjects neuroendocrine ( mixed type ) tumor exclude . 2 . Pancreatic cancer surgical staging : T 13 , N01 , M0 . 3 . Subject able start treatment later 12 week postsurgery . 4 . ≥18 year age time sign informed consent form ( ICF ) . 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . 6 . Acceptable hematology parameter : Absolute neutrophil count ≥1500 cell/mm3 Platelet count ≥100,000/mm3 Hemoglobin ( Hgb ) ≥9 g/dL 7 . Acceptable blood chemistry level : Aspartate aminotransferase ( AST ) / Serum glutamic oxaloacetic transaminase ( SGOT ) Alanine transaminase ( ALT ) / Serum glutamic pyruvic transaminase ( SGPT ) ≤2.5 × upper limit normal range ( ULN ) Total bilirubin ≤ Upper Limit Normal ( ULN ) ( subject Gilbert 's syndrome bilirubin 1.5 x ULN ) Alkaline phosphatase ≤ 2.5 x ULN Serum creatinine within upper limit normal calculated clearance ≥50 mL/min/1.73 m2 . If use creatinine clearance , actual body weight used calculate creatinine clearance ( eg , use CockroftGault formula ) . For subject Body Mass Index ( BMI ) &gt; 30 kg/m2 , lean body weight use instead 8 . Cancer antigen ( CA ) 199 &lt; 100 U/mL assess within 14 day randomization 9 . Acceptable coagulation study demonstrate Prothrombin Time ( PT ) Partial Thromboplastin Time ( PTT ) within normal limit ( ±15 % ) 1 . Prior neoadjuvant treatment radiation therapy pancreatic adenocarcinoma 2 . Presence history metastatic pancreatic adenocarcinoma 3 . .Any malignancy within 5 year prior randomization , exception adequately treat insitu carcinoma cervix , uteri , nonmelanomatous skin cancer ( treatment complete 6 month prior randomization ) 4 . Active , uncontrolled bacterial , viral , fungal infection ( ) require systemic therapy , define ongoing signs/symptoms related infection without improvement despite appropriate antibiotic , antiviral therapy , and/or treatment 5 . Known infection hepatitis B C , history human immunodeficiency virus ( HIV ) infection , subject receive immunosuppressive myelosuppressive medication would opinion investigator , increase risk serious neutropenic complication 6 . History allergy hypersensitivity nabpaclitaxel gemcitabine excipients 7 . Serious medical risk factor involve major organ system , serious psychiatric disorder , could compromise subject 's safety study data integrity . These include , limited : 1 ) .History connective tissue disorder ( eg , lupus , scleroderma , arteritis nodosa ) 2 ) .History interstitial lung disease , slowly progressive dyspnea unproductive cough , sarcoidosis , silicosis , idiopathic pulmonary fibrosis , pulmonary hypersensitivity pneumonitis multiple allergy 3 ) .History follow within 6 month prior Cycle 1 Day 1 : myocardial infarction , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , New York Heart Association ( NYHA ) Class IIIIV heart failure , uncontrolled hypertension , clinically significant cardiac dysrhythmia ECG abnormality , cerebrovascular accident , transient ischemic attack , seizure disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>